Have a feature idea you'd love to see implemented?
Let us know!
BRNS Barinthus Biotherapeutics Plc.
Price (delayed)
$0.9883
Market cap
$39.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.49
Enterprise value
-$53.68M
vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed
Highlights
BRNS's revenue has surged by 106% year-on-year
The gross profit has surged by 106% year-on-year
Barinthus Biotherapeutics's quick ratio has decreased by 38% YoY and by 7% from the previous quarter
The equity has contracted by 15% YoY
Key stats
What are the main financial stats of BRNS
Market
Valuations
Earnings
Shares outstanding
40.23M
Market cap
$39.76M
Enterprise value
-$53.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.24
Price to sales (P/S)
2.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.59
Revenue
$14.97M
EBIT
-$58.65M
EBITDA
-$51.21M
Free cash flow
-$62.09M
Per share
Balance sheet
Liquidity
EPS
-$1.49
Free cash flow per share
-$1.58
Book value per share
$4.04
Revenue per share
$0.38
TBVPS
$3.9
Total assets
$188.69M
Total liabilities
$29.23M
Debt
$12.67M
Equity
$159.29M
Working capital
$119.58M
Debt to equity
0.08
Current ratio
8.93
Quick ratio
7.04
Net debt/EBITDA
1.82
Margins
Efficiency
Dividend
EBITDA margin
-342.1%
Gross margin
100%
Net margin
-386.3%
Operating margin
-431.3%
Return on assets
-29.3%
Return on equity
-34.3%
Return on invested capital
-163%
Return on capital employed
-33.8%
Return on sales
-391.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BRNS stock price
How has the Barinthus Biotherapeutics stock price performed over time
Intraday
9.93%
1 week
-28.38%
1 month
-25.89%
1 year
-63.67%
YTD
-73.22%
QTD
-16.95%
Financial performance
How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$14.97M
Gross profit
$14.97M
Operating income
-$64.57M
Net income
-$57.83M
Gross margin
100%
Net margin
-386.3%
BRNS's revenue has surged by 106% year-on-year
The gross profit has surged by 106% year-on-year
The operating margin has soared by 65% YoY
The net margin has soared by 64% YoY
Growth
What is Barinthus Biotherapeutics's growth rate over time
Valuation
What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.24
P/S
2.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.59
Barinthus Biotherapeutics's EPS has increased by 27% YoY and by 10% from the previous quarter
The stock's price to book (P/B) is 52% less than its last 4 quarters average of 0.5
The equity has contracted by 15% YoY
BRNS's revenue has surged by 106% year-on-year
Efficiency
How efficient is Barinthus Biotherapeutics business performance
Barinthus Biotherapeutics's ROS has soared by 65% YoY
Barinthus Biotherapeutics's return on invested capital has increased by 31% YoY and by 16% QoQ
BRNS's return on assets is up by 13% year-on-year and by 6% since the previous quarter
The return on equity has increased by 11% year-on-year and by 6% since the previous quarter
Dividends
What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BRNS.
Financial health
How did Barinthus Biotherapeutics financials performed over time
Barinthus Biotherapeutics's quick ratio has decreased by 38% YoY and by 7% from the previous quarter
The current ratio fell by 28% YoY but it rose by 6% QoQ
The debt is 92% lower than the equity
The equity has contracted by 15% YoY
BRNS's debt to equity is up by 14% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.